Biotech Pharmaceutical
Dynamis Therapeutics is focused on the discovery and development of therapeutic pharmaceuticals to treat and prevent diabetic complications resulting from glucose induced glycation and oxidative stress. Now, Dynamis brings its discovery out of the laboratory with MEG 21 ? a unique skin treatment that delivers the compound Supplaminer deep into skin to reduce inflammation and free radicals, allow normal collagen production and reverse cross-linking.